1)BRCA1/2 Mutations: BRCA1/2 mutations are critical pathogenic factors in ovarian cancer, and PARP inhibitors have demonstrated significant efficacy in tumors harboring BRCA mutations. Here, BRCA1 is linked to ovarian carcinoma.